KPV
Tissue & recoveryAlso known as Lys-Pro-Val, alpha-MSH (11-13)
Evidence tier
Limited published literature
17 publications over 27 years · trials not yet curated
- Researched since
- 1999
- Publications
- 17
- Mean purity
- 99.5%
- Vendors listing
- 25
American Peptides shows the highest mean assayed purity for KPV at 99.9% across 1 lot record. Purity figures below come from the certificates named in each row.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 1999 — 27 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
17 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.5% across 19 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.41 pts purity across lots, mean label deviation 8.1%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
25 of 25 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
14 of 19 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is KPV?
A tripeptide (lysine-proline-valine) corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone, studied for anti-inflammatory signalling.
Studied in published research for anti-inflammatory and gut-health applications.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Published work is preclinical, in cell and animal models of inflammation. PepIndex does not evaluate clinical significance and does not describe administration.
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease — Inflammatory bowel diseases (2008)
Peer-reviewed article indexed in PubMed, published in Inflammatory bowel diseases (2008).
- Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis — Molecular therapy : the journal of the American Society of Gene Therapy (2017)
Peer-reviewed article indexed in PubMed, published in Molecular therapy : the journal of the American Society of Gene Therapy (2017).
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation — Gastroenterology (2008)
Peer-reviewed article indexed in PubMed, published in Gastroenterology (2008).
- Structural modification of the tripeptide KPV by reductive "glycoalkylation" of the lysine residue — PloS one (2018)
Peer-reviewed article indexed in PubMed, published in PloS one (2018).
- Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists — International journal of physiology, pathophysiology and pharmacology (2012)
Peer-reviewed article indexed in PubMed, published in International journal of physiology, pathophysiology and pharmacology (2012).
- Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model — Gastroenterology (2010)
Peer-reviewed article indexed in PubMed, published in Gastroenterology (2010).
- Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide — Experimental eye research (2006)
Peer-reviewed article indexed in PubMed, published in Experimental eye research (2006).
- New insights into the functions of alpha-MSH and related peptides in the immune system — Annals of the New York Academy of Sciences (2003)
Peer-reviewed article indexed in PubMed, published in Annals of the New York Academy of Sciences (2003).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.
Vendor comparison
| Vendor | Score here | Price / mg | Certificates | Mean purity | Label deviation | Get it |
|---|---|---|---|---|---|---|
| CuroISO/IEC 17025 | 93.877% | — | 1 | 99.6% | 27.0% | |
| Ascend ScienceISO/IEC 17025 | 90.291% | — | 1 | 99.7% | 4.5% | |
| PeptidePlugs | 89.790% | — | 3 | 99.7% | 9.3% | |
| Hydro Research PeptidesISO/IEC 17025 | 88.289% | — | 1 | 98.2% | 26.6% | |
| American PeptidesISO/IEC 17025 | 86.5100% | $6.00 (100%) | 1 | 99.9% | 1.4% | |
| Koi Peptides | 83.194% | $5.00 (83%) | 1 | 99.6% | 4.6% | |
| Ascension Peptides | 81.486% | $5.00 (83%) | 0 | — | — | |
| NeuroLabs Research | 81.486% | $5.00 (83%) | 0 | — | — | |
| Protide Health | 80.694% | $7.00 (117%) | 0 | — | — | |
| Northline LabsISO/IEC 17025 | 80.393% | $7.50 (125%) | 0 | — | — | |
| ZC Labs | 79.384% | — | 2 | 99.6% | 12.6% | |
| Good Science Bio | 79.275% | $3.50 (58%) | 0 | — | — | |
| Evo Labs Research | 7989% | $5.00 (83%) | 0 | — | — | |
| Licensed Peptides | 7789% | — | 1 | 99.8% | 2.1% | |
| Modern AminosISO/IEC 17025 | 74100% | — | 1 | 99.8% | 19.4% | |
| Simple Peptide | 7489% | — | 1 | 99.9% | 5.1% | |
| Next Gen PeptidesISO/IEC 17025 | 73.897% | $12.00 (200%) | 2 | 99.7% | 2.5% | |
| Vertex Labs | 70.170% | — | 1 | 99.7% | 0.6% | |
| Improved Peptides | 7089% | $6.00 (100%) | 0 | — | — | |
| Eternal Peptides | 69.365% | $5.00 (83%) | 0 | — | — | |
| Extreme Peptides | 64.282% | — | 1 | 99.2% | 1.0% | |
| GenX Peptides | 61.468% | $8.00 (133%) | 0 | — | — | |
| BioLongevity Labs | 59.274% | $10.00 (167%) | 0 | — | — | |
| Mile High Compounds | 57.494% | $8.00 (133%) | 2 | 99.0% | 1.7% | |
| Sports Technology Labs | 54.974% | $10.40 (173%) | 0 | — | — |
Certificate records
| Vendor | Lot | Tested | Lab | Labeled | Assayed | Discrepancy | Purity | Source |
|---|---|---|---|---|---|---|---|---|
| Vertex Labs | 2608190846 | Freedom Diagnostics Testing | 10 mg | 9.94 mg | 0.6% | 99.7% | Vendor-published | |
| Next Gen Peptides | KP10-06 | ILS Laboratories | 10 mg | 10.26 mg | 2.6% | 99.7% | Vendor-published | |
| ZC Labs | ZCLa2607160041 | Freedom Diagnostics Testing | 10 mg | 11.01 mg | 10.1% | 99.5% | Vendor-published | |
| PeptidePlugs | 101-05-ZB | Freedom Diagnostics Testing | 10 mg | 11.14 mg | 11.4% | 99.5% | Vendor-published | |
| Curo | KPV10ZO626 | BTLabs | 10 mg | 12.7 mg | 27.0% | 99.6% | Vendor-published | |
| Simple Peptide | KPV10-072026-1 | Analysis FreedomDiagnostics | 10 mg | 10.51 mg | 5.1% | 99.9% | Vendor-published | |
| Ascend Science | AS-KPV10 | Kovera Labs and/or ILS Labs | 10 mg | 10.45 mg | 4.5% | 99.7% | Vendor-published | |
| PeptidePlugs | 144-03-DK | Freedom Diagnostics Testing | 10 mg | 8.94 mg | 10.6% | 99.8% | Vendor-published | |
| Hydro Research Peptides | HR-2026-4981 | Hydro Research | 10 mg | 12.66 mg | 26.6% | 98.2% | Vendor-published | |
| Koi Peptides | 612026KP | Principal Chemist | 10 mg | 10.46 mg | 4.6% | 99.6% | Vendor-published | |
| ZC Labs | ZCLa2606080086 | Freedom Diagnostics Testing | 10 mg | 11.51 mg | 15.1% | 99.8% | Vendor-published | |
| Next Gen Peptides | KP10-05 | ILS Laboratories | 10 mg | 10.25 mg | 2.5% | 99.7% | Vendor-published | |
| Modern Aminos | BX-P-U1D0 | Analysis FreedomDiagnostics | 10 mg | 11.94 mg | 19.4% | 99.8% | Vendor-published | |
| PeptidePlugs | 112-U-A | Freedom Diagnostics Testing | 10 mg | 9.41 mg | 5.9% | 99.7% | Vendor-published | |
| American Peptides | KPV10-0318 | Excellence in HPLC-MS Analysis | 10 mg | 9.86 mg | 1.4% | 99.9% | Vendor-published | |
| Extreme Peptides | EXT-KPV-00004 | Richard Sylvester MD | 5.73 mg | 5.67 mg | 1.0% | 99.2% | Vendor-published | |
| Licensed Peptides | KPV-XXX-01 | Vanguard Laboratory | 10 mg | 10.21 mg | 2.1% | 99.8% | Vendor-published | |
| Mile High Compounds | KCP-500-MH-02 | Independent Third-Party Lab | 30 mg | 30.5 mg | 1.7% | 99.0% | Vendor-published | |
| Mile High Compounds | KCP-500-MH-01 | Independent Third-Party Lab | 30 mg | 29.5 mg | 1.7% | 99.0% | Vendor-published |